The Experts below are selected from a list of 1047 Experts worldwide ranked by ideXlab platform
Robert I. Henkin - One of the best experts on this subject based on the ideXlab platform.
-
A genetic marker of the ACKR1 gene is present in patients with Type II congenital smell loss who have type I hyposmia and Hypogeusia.
American journal of otolaryngology, 2015Co-Authors: William A. Stateman, Alexandra B. Knöppel, Willy A. Flegel, Robert I. HenkinAbstract:Abstract Purpose Our previous study of Type II congenital smell loss patients revealed a statistically significant lower prevalence of an FY (ACKR1, formerly DARC) haplotype compared to controls. The present study correlates this genetic feature with subgroups of patients defined by specific smell and taste functions. Methods Smell and taste function measurements were performed by use of olfactometry and gustometry to define degree of abnormality of smell and taste function. Smell loss was classified as anosmia or hyposmia (types I, II or III). Taste loss was similarly classified as ageusia or Hypogeusia (types I, II or III). Based upon these results patient erythrocyte antigen expression frequencies were categorized by smell and taste loss with results compared between patients within the Type II group and published controls. Results Comparison of antigen expression frequencies revealed a statistically significant decrease in incidence of an Fyb haplotype only among patients with type I hyposmia and any form of taste loss (Hypogeusia). In all other patient groups erythrocyte antigens were expressed at normal frequencies. Conclusions Data suggest that Type II congenital smell loss patients who exhibit both type I hyposmia and Hypogeusia are genetically distinct from all other patients with Type II congenital smell loss. This distinction is based on decreased Fyb expression which correlated with abnormalities in two sensory modalities (hyposmia type I and Hypogeusia). Only patients with these two specific sensory abnormalities expressed the Fyb antigen (encoded by the ACKR1 gene on the long arm of chromosome 1) at frequencies different from controls.
-
Taste and smell function in chronic disease: a review of clinical and biochemical evaluations of taste and smell dysfunction in over 5000 patients at The Taste and Smell Clinic in Washington, DC.
American journal of otolaryngology, 2013Co-Authors: Robert I. Henkin, Lucien M. Levy, April FordyceAbstract:Abstract Purpose To describe systematic methods developed over 40 years among over 5000 patients at The Taste and Smell Clinic in Washington, DC to evaluate taste and smell dysfunction. Materials and Methods A tripartite methodology was developed. First, methods to determine clinical pathology underlying the multiple disease processes responsible for taste and smell dysfunction were developed. Second, methods to determine biochemical parameters responsible for these pathologies were developed. Third, methods to implement these techniques were developed to form a unified basis upon which treatment strategies can be developed to treat these patients. Results Studies were performed in 5183 patients. Taste loss was present in 62% of patients, smell loss in 87%. Most patients with taste loss (52%) exhibited Type II Hypogeusia; most patients with smell loss (56%) exhibited Type II hyposmia. Sensory distortions were present in 60%. Four common diagnostic entities were found: post influenza-type hyposmia and Hypogeusia (27% of patients), idiopathic causes (16%), allergic rhinitis (15%) and post head injury (14%). Regardless of clinical diagnosis the major biochemical abnormality found in most patients (~ 70%) was diminished parotid salivary and nasal mucus secretion of cAMP and cGMP. Conclusions Taste and smell dysfunctions are common clinical problems associated with chronic disease processes. These symptoms require a systematic, integrated approach to understand their multiple and complex components. The approach presented here can and has led to effective treatment.
-
Intranasal Theophylline Treatment of Hyposmia and Hypogeusia: A Pilot Study
Archives of otolaryngology--head & neck surgery, 2012Co-Authors: Robert I. Henkin, Michael Schultz, Laura Minnick-poppeAbstract:Objective To determine whether intranasal theophylline methylpropyl paraben can correct hyposmia and Hypogeusia. Design We performed an open-label pilot study in patients with hyposmia and Hypogeusia under the following 3 conditions: (1) before treatment, (2) after oral theophylline anhydrous treatment, and (3) after intranasal theophylline treatment. Under each condition, we performed subjective evaluations of taste and smell functions, quantitative measurements of taste (gustometry) and smell (olfactometry), and measurements of serum theophylline level and body weight. Setting The Taste and Smell Clinic in Washington, DC. Patients Ten patients with hyposmia and Hypogeusia clinically related to the effects of viral illness, allergic rhinitis, traumatic brain injury, congenital hyposmia, and other chronic disease processes were selected. Interventions Oral theophylline anhydrous, 200 to 800 mg/d for 2 to 12 months, was administered to each patient. This treatment was discontinued for 3 weeks to 4 months when intranasal theophylline methylpropyl paraben, 20 μg/d in each naris, was administered for 4 weeks. Main Outcome Measures At termination of each condition, taste and smell function was determined subjectively, by means of gustometry and olfactometry, with measurement of serum theophylline levels and body weight. Results Oral theophylline treatment improved taste and smell acuity in 6 patients after 2 to 12 months of treatment. Intranasal theophylline treatment improved taste and smell acuity in 8 patients after 4 weeks, with improvement greater than after oral administration. No adverse effects accompanied intranasal drug use. Body weight increased with each treatment but was greater after intranasal than after oral administration. Conclusions Intranasal theophylline treatment is safer and more effective in improving hyposmia and Hypogeusia than oral theophylline anhydrous treatment.
-
drug induced taste and smell disorders incidence mechanisms and management related primarily to treatment of sensory receptor dysfunction
Drug Safety, 1994Co-Authors: Robert I. HenkinAbstract:Drugs in every major pharmacological category can impair both taste and smell function and do so more commonly than presently appreciated. Impairment usually affects sensory function at a molecular level, causing 2 major behavioural changes — loss of acuity (i.e. Hypogeusia and hyposmia) and/or distortion of function (i.e. dysgeusia and dysosmia). These changes can impair appetite, food intake, cause significant lifestyle changes and may require discontinuation of drug administration.
-
Drug-Induced Taste and Smell Disorders
Drug safety, 1994Co-Authors: Robert I. HenkinAbstract:Drugs in every major pharmacological category can impair both taste and smell function and do so more commonly than presently appreciated. Impairment usually affects sensory function at a molecular level, causing 2 major behavioural changes — loss of acuity (i.e. Hypogeusia and hyposmia) and/or distortion of function (i.e. dysgeusia and dysosmia). These changes can impair appetite, food intake, cause significant lifestyle changes and may require discontinuation of drug administration.
Catherine A Heyneman - One of the best experts on this subject based on the ideXlab platform.
-
Zinc deficiency and taste disorders.
Annals of Pharmacotherapy, 1996Co-Authors: Catherine A HeynemanAbstract:Elemental zinc supplementation in daily dosages of 25-100 mg po appears to be an efficacious treatment for taste dysfunction secondary to zinc depletion. Insufficient evidence is available to determine the efficacy of zinc supplementation for the treatment of Hypogeusia or dysgeusia secondary to drug therapy or medical conditions that do not involve low serum zinc concentrations.
Naomi Hayashida - One of the best experts on this subject based on the ideXlab platform.
-
awareness of dysgeusia and gustatory tests in patients undergoing chemotherapy for breast cancer
Supportive Care in Cancer, 2018Co-Authors: Sayaka Kuba, Michi Morita, Toshiko Hatachi, Megumi Matsumoto, Kosho Yamanouchi, Chika Sakimura, Mitsuhisa Takatsuki, Hiroshi Yano, Rie Fujiyama, Naomi HayashidaAbstract:We analyzed the prevalence of gustatory test abnormalities in breast cancer (BC) patients undergoing chemotherapy. We enrolled 43 BC patients undergoing chemotherapy and 38 BC patients who had never undergone chemotherapy (control group). Two gustatory tests were conducted: an instillation method examining the threshold for four basic taste stimuli and an electrogustometry method measuring the threshold for perception with electric stimulation at the front two-thirds of the tongue (cranial nerve VII) and at the back third of the tongue (cranial nerve IX). The results of the two gustatory tests and clinicopathological factors were compared between the chemotherapy and control groups and between patients with and without awareness of dysgeusia in the chemotherapy group. In the chemotherapy group, 19 (44%) patients were aware of dysgeusia and 8 (19%) had Hypogeusia using the instillation method. Although more patients had parageusia in the chemotherapy than control group, no significant differences in the results of the two gustatory tests were observed. Patients with dysgeusia awareness had a higher threshold at cranial nerve IX using the electrogustometry method than those without dysgeusia awareness; no significant differences in Hypogeusia were observed using the instillation method. In fact, 74% (14/19) of patients with dysgeusia awareness could identify the four tastes accurately using the instillation method. Similar results were observed for the instillation and electrogustometry methods at cranial nerve VII. While approximately half of the chemotherapy patients were aware of dysgeusia, 81% (35/43) of them could accurately identify the four basic tastes using the instillation method.
-
Awareness of dysgeusia and gustatory tests in patients undergoing chemotherapy for breast cancer
Supportive Care in Cancer, 2018Co-Authors: Sayaka Kuba, Michi Morita, Toshiko Hatachi, Megumi Matsumoto, Kosho Yamanouchi, Chika Sakimura, Mitsuhisa Takatsuki, Hiroshi Yano, Rie Fujiyama, Naomi HayashidaAbstract:Purpose We analyzed the prevalence of gustatory test abnormalities in breast cancer (BC) patients undergoing chemotherapy. Methods We enrolled 43 BC patients undergoing chemotherapy and 38 BC patients who had never undergone chemotherapy (control group). Two gustatory tests were conducted: an instillation method examining the threshold for four basic taste stimuli and an electrogustometry method measuring the threshold for perception with electric stimulation at the front two-thirds of the tongue (cranial nerve VII) and at the back third of the tongue (cranial nerve IX). The results of the two gustatory tests and clinicopathological factors were compared between the chemotherapy and control groups and between patients with and without awareness of dysgeusia in the chemotherapy group. Results In the chemotherapy group, 19 (44%) patients were aware of dysgeusia and 8 (19%) had Hypogeusia using the instillation method. Although more patients had parageusia in the chemotherapy than control group, no significant differences in the results of the two gustatory tests were observed. Patients with dysgeusia awareness had a higher threshold at cranial nerve IX using the electrogustometry method than those without dysgeusia awareness; no significant differences in Hypogeusia were observed using the instillation method. In fact, 74% (14/19) of patients with dysgeusia awareness could identify the four tastes accurately using the instillation method. Similar results were observed for the instillation and electrogustometry methods at cranial nerve VII. Conclusions While approximately half of the chemotherapy patients were aware of dysgeusia, 81% (35/43) of them could accurately identify the four basic tastes using the instillation method.
Sayaka Kuba - One of the best experts on this subject based on the ideXlab platform.
-
awareness of dysgeusia and gustatory tests in patients undergoing chemotherapy for breast cancer
Supportive Care in Cancer, 2018Co-Authors: Sayaka Kuba, Michi Morita, Toshiko Hatachi, Megumi Matsumoto, Kosho Yamanouchi, Chika Sakimura, Mitsuhisa Takatsuki, Hiroshi Yano, Rie Fujiyama, Naomi HayashidaAbstract:We analyzed the prevalence of gustatory test abnormalities in breast cancer (BC) patients undergoing chemotherapy. We enrolled 43 BC patients undergoing chemotherapy and 38 BC patients who had never undergone chemotherapy (control group). Two gustatory tests were conducted: an instillation method examining the threshold for four basic taste stimuli and an electrogustometry method measuring the threshold for perception with electric stimulation at the front two-thirds of the tongue (cranial nerve VII) and at the back third of the tongue (cranial nerve IX). The results of the two gustatory tests and clinicopathological factors were compared between the chemotherapy and control groups and between patients with and without awareness of dysgeusia in the chemotherapy group. In the chemotherapy group, 19 (44%) patients were aware of dysgeusia and 8 (19%) had Hypogeusia using the instillation method. Although more patients had parageusia in the chemotherapy than control group, no significant differences in the results of the two gustatory tests were observed. Patients with dysgeusia awareness had a higher threshold at cranial nerve IX using the electrogustometry method than those without dysgeusia awareness; no significant differences in Hypogeusia were observed using the instillation method. In fact, 74% (14/19) of patients with dysgeusia awareness could identify the four tastes accurately using the instillation method. Similar results were observed for the instillation and electrogustometry methods at cranial nerve VII. While approximately half of the chemotherapy patients were aware of dysgeusia, 81% (35/43) of them could accurately identify the four basic tastes using the instillation method.
-
Awareness of dysgeusia and gustatory tests in patients undergoing chemotherapy for breast cancer
Supportive Care in Cancer, 2018Co-Authors: Sayaka Kuba, Michi Morita, Toshiko Hatachi, Megumi Matsumoto, Kosho Yamanouchi, Chika Sakimura, Mitsuhisa Takatsuki, Hiroshi Yano, Rie Fujiyama, Naomi HayashidaAbstract:Purpose We analyzed the prevalence of gustatory test abnormalities in breast cancer (BC) patients undergoing chemotherapy. Methods We enrolled 43 BC patients undergoing chemotherapy and 38 BC patients who had never undergone chemotherapy (control group). Two gustatory tests were conducted: an instillation method examining the threshold for four basic taste stimuli and an electrogustometry method measuring the threshold for perception with electric stimulation at the front two-thirds of the tongue (cranial nerve VII) and at the back third of the tongue (cranial nerve IX). The results of the two gustatory tests and clinicopathological factors were compared between the chemotherapy and control groups and between patients with and without awareness of dysgeusia in the chemotherapy group. Results In the chemotherapy group, 19 (44%) patients were aware of dysgeusia and 8 (19%) had Hypogeusia using the instillation method. Although more patients had parageusia in the chemotherapy than control group, no significant differences in the results of the two gustatory tests were observed. Patients with dysgeusia awareness had a higher threshold at cranial nerve IX using the electrogustometry method than those without dysgeusia awareness; no significant differences in Hypogeusia were observed using the instillation method. In fact, 74% (14/19) of patients with dysgeusia awareness could identify the four tastes accurately using the instillation method. Similar results were observed for the instillation and electrogustometry methods at cranial nerve VII. Conclusions While approximately half of the chemotherapy patients were aware of dysgeusia, 81% (35/43) of them could accurately identify the four basic tastes using the instillation method.
Arwa M. Farag - One of the best experts on this subject based on the ideXlab platform.
-
Influence of smoking history on the perception of radiation-induced dysgeusia/Hypogeusia in patients with head and neck cancer
European Archives of Oto-Rhino-Laryngology, 2020Co-Authors: Damin Park, Shruti Jain, Zachary Quay-de La Vallee, Kathryn Huber, Miriam O’leary, Arwa M. FaragAbstract:Objectives This investigation aimed to assess the effect of smoking on the onset and resolution of dysgeusia/Hypogeusia in head and neck cancer (HNC) patients receiving radiotherapy (XRT). Materials and methods This is a retrospective cohort investigation of HNC patients treated with XRT. Data collected from the patients’ medical records included demographics, primary cancer diagnoses, HNC therapeutic modalities, smoking status, and dates of onset/resolution of dysgeusia/Hypogeusia. Results A 103 met inclusion criteria, of which 61.8% developed dysgeusia/Hypogeusia. Mean age was 58.3 ± 12.9 and 66% were either former or current smokers. Never smokers seemed to be at higher, but statistically insignificant, the risk for developing dysgeusia/Hypogeusia than former or current smokers [HR 1.05 and 1.66; 95% CI (0.60, 1.84) and (0.85, 3.24)]. They were also less likely to recover when compared to former smokers [HR 0.74; 95% CI (0.39, 1.39)]. Although statistically insignificant, never smokers showed rapid dysgeusia/Hypogeusia onset after XRT compared to former or current smokers (median 14 days versus 22 and 9 days, respectively; p = 0.25). Never smokers showed quicker but statistically insignificant, recovery time compared to former or current smokers (median 113 days versus 149 and 238 days, respectively; p = 0.57). Conclusion Although results lacked statistical significance, never smokers receiving XRT were prone to higher risk and faster onset of dysgeusia/Hypogeusia than former and current smokers.
-
influence of smoking history on the perception of radiation induced dysgeusia Hypogeusia in patients with head and neck cancer
European Archives of Oto-rhino-laryngology, 2020Co-Authors: Damin Park, Shruti Jain, Arwa M. Farag, Zachary Quayde La Vallee, Kathryn E Huber, Miriam A OlearyAbstract:Objectives This investigation aimed to assess the effect of smoking on the onset and resolution of dysgeusia/Hypogeusia in head and neck cancer (HNC) patients receiving radiotherapy (XRT). Materials and methods This is a retrospective cohort investigation of HNC patients treated with XRT. Data collected from the patients' medical records included demographics, primary cancer diagnoses, HNC therapeutic modalities, smoking status, and dates of onset/resolution of dysgeusia/Hypogeusia. Results A 103 met inclusion criteria, of which 61.8% developed dysgeusia/Hypogeusia. Mean age was 58.3 ± 12.9 and 66% were either former or current smokers. Never smokers seemed to be at higher, but statistically insignificant, the risk for developing dysgeusia/Hypogeusia than former or current smokers [HR 1.05 and 1.66; 95% CI (0.60, 1.84) and (0.85, 3.24)]. They were also less likely to recover when compared to former smokers [HR 0.74; 95% CI (0.39, 1.39)]. Although statistically insignificant, never smokers showed rapid dysgeusia/Hypogeusia onset after XRT compared to former or current smokers (median 14 days versus 22 and 9 days, respectively; p = 0.25). Never smokers showed quicker but statistically insignificant, recovery time compared to former or current smokers (median 113 days versus 149 and 238 days, respectively; p = 0.57). Conclusion Although results lacked statistical significance, never smokers receiving XRT were prone to higher risk and faster onset of dysgeusia/Hypogeusia than former and current smokers.